BioCentury
ARTICLE | Finance

Eyeing POC

PolyActiva B round to complete POC for drug polymer conjugates for eyes

February 25, 2013 8:00 AM UTC

Ophthalmic play PolyActiva Pty. Ltd. will use its A$9.2 million ($9.5 million) series B round to complete clinical proof-of-concept testing for at least one drug polymer conjugate program and possibly a second.

New investor Yuuwa Capital and undisclosed angel investors participated in the round, which was led by existing investor Brandon Capital Partners...